Neurocrine Biosciences, Inc. (LON:0K6R)
 137.64
 -10.63 (-7.17%)
  At close: Oct 29, 2025
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $794.90M USD in the quarter ending September 30, 2025, with 27.78% growth. This brings the company's revenue in the last twelve months to $2.68B, up 19.61% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm) 
 $2.68B
Revenue Growth 
 +19.61%
P/S Ratio 
 5.25
Revenue / Employee 
 $1.49M
Employees 
 1,800
Market Cap 
10.47B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% | 
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% | 
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% | 
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% | 
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Neurocrine Biosciences News
- 2 days ago - Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Neurocrine Biosciences Reports Third Quarter 2025 Financial Results - PRNewsWire
- 10 days ago - Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq
- 10 days ago - Neurocrine Biosciences (NBIX): Citigroup Initiates Coverage with 'Buy' Rating | NBIX Stock News - GuruFocus
- 11 days ago - Morgan Stanley Raises Price Target for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus
- 13 days ago - Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches - Seeking Alpha
- 14 days ago - Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study - Nasdaq
- 14 days ago - Neurocrine (NBIX) Reports Promising Long-Term Efficacy of INGREZZA in Tardive Dyskinesia - GuruFocus